Status:

COMPLETED

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

Lead Sponsor:

AstraZeneca

Conditions:

Healthy Elderly Volunteers

Mild-to-moderate Alzheimer's Disease Patients

Eligibility:

All Genders

55-80 years

Phase:

PHASE1

Brief Summary

This is a two-part multiple dose study in healthy male and female (of non-child bearing potential) elderly volunteers, and in Alzheimer's disease patients, to assess the safety, effects on the body, a...

Detailed Description

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Plasma and ...

Eligibility Criteria

Inclusion

  • Part 1: Healthy elderly male and female (of non-childbearing potential) subjects.
  • Part 2: Male and non-fertile female AD patients.
  • Body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg.
  • Part 2: Clinical diagnosis of probable AD according to the NINCDS-ADRDA criteria.
  • Part 2: Manifestation of AD symptoms at least 6 months before randomization.

Exclusion

  • Part 1: History or presence of psychiatric disease/condition, GI, renal, hepatic, cardiovascular, psychiatric, or retinal diseases or disorders.
  • Part 2: Significant disease affecting the CNS other than Alzheimer's disease, including but not limited to other dementias, other significant neurological or major psychiatric disease.
  • History of use of antipsychotic drugs , or chronic use of antidepressant or anxiolytic drugs.
  • Frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other nicotine products.
  • History of neurological disease, including seizures, recent memory impairment, or clinically significant head injury.

Key Trial Info

Start Date :

March 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2014

Estimated Enrollment :

47 Patients enrolled

Trial Details

Trial ID

NCT01795339

Start Date

March 1 2013

End Date

March 1 2014

Last Update

April 3 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Research Site

Glendale, California, United States